Lubiprostone: A chloride channel activator for treatment of chronic constipation

Annals of Pharmacotherapy

Volumn 41, Issue 6, 2007, Pages 957-964

  Ambizas, Emily M ^a,b   Ginzburg, Regina ^a,c  

^a ST JOHN'S UNIVERSITY   (United States)

^b Brooks Eckerd Pharmacy   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Amitiza; Chronic constipation; Lubiprostone

Indexed keywords

BISACODYL; CHLORIDE CHANNEL; DOCUSATE SODIUM; EMOLLIENT AGENT; GLYCEROL; ISPAGULA; KRISTALOSE; LACTULOSE; LAXATIVE; LUBIPROSTONE; LUBRICATING AGENT; MACROGOL 3350; MAGNESIUM CITRATE; MAGNESIUM HYDROXIDE; METHYLCELLULOSE; MINERAL OIL; POLYCARBOPHIL; POLYCARBOPHIL CALCIUM; SENOKOT; SODIUM DIHYDROGEN PHOSPHATE; TEGASEROD; UNCLASSIFIED DRUG; DRUG DERIVATIVE; FATTY ACID; PROSTAGLANDIN E1;

ABDOMINAL CRAMP; ABDOMINAL DISCOMFORT; ABDOMINAL DISTENSION; ABDOMINAL PAIN; AREA UNDER THE CURVE; ASPIRATION PNEUMONIA; BLOATING; CHRONIC DISEASE; CLINICAL TRIAL; CONSTIPATION; DEHYDRATION; DIARRHEA; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDICATION; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROLYTE DISTURBANCE; FLATULENCE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL OBSTRUCTION; HEADACHE; HUMAN; INTESTINE MOTILITY; INTESTINE TRANSIT TIME; IRRITABLE COLON; KIDNEY FAILURE; MELANOSIS; NAUSEA; NONHUMAN; PRIORITY JOURNAL; RECTAL IRRITATION; RECTUM DISEASE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; STOMACH FUNCTION; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VERNER MORRISON SYNDROME; VITAMIN METABOLISM; VOMITING; DRUG POTENTIATION;

ALPROSTADIL; CHLORIDE CHANNELS; CHRONIC DISEASE; CONSTIPATION; FATTY ACIDS; HUMANS;

EID: 34250210742     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1K047     Document Type: Review

References (32)

1. Higgins PD, Johanson JF. Epidemiology of constipation in North America: a systematic review. Am J Gastroenterol 2004;99:750-9.
2. Pare P, Ferrazzi S, Thompson WG, Irvine EJ, Rance L. An epidemiological survey of constipation in Canada: definitions, rates, demographics, and predictors of health care seeking. Am J Gastroenterol 2001;96:3130-7.
3. Sonnenberg A, Koch TR. Physician visits in the United States for constipation: 1958 to 1986. Dig Dis Sci 1989;34:606-11.
4. Faigel DO. A clinical approach to constipation. Clin Cornerstone 2002;4:11-21.
5. Levy S. Drug outlets remain leader in laxative sales. Drug Topics. www.drugtopics.com/drugtopics/article/articleDetail.jsp?id=116596 (accessed 2007 Jan 5).
6. Dennison C, Prasad M, Lloyd A, Bhattacharyya SK, Dhawan R, Coyne K. The health-related quality of life and economic burden of constipation. Pharmacoeconomics 2005;23:461-76.
7. Irvine EJ, Ferrazzi S, Pare P, Thompson WG, Rance L. Health-related quality of life in functional GI disorders: focus on constipation and resource utilization. Am J Gastroenterol 2002;97:1986-93.
8. Xiao ZL, Pricolo V, Biancani P, Behar J. Role of progesterone signaling in the regulation of G-protein levels in female chronic constipation. Gastroenterology 2005;128:667-75.
9. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006;130:1480-91.
10. Lembo A, Camilleri M. Chronic constipation. N Engl J Med 2003;349:1360-8.
11. Velio P, Bassotti G. Chronic idiopathic constipation: pathophysiology and treatment. J Clin Gastroenterol 1996;22:190-6.
12. Wald A. Constipation in the primary care setting: current concepts and misconceptions. Am J Med 2006;119:736-9.
13. Red book 2006. Montvale, NJ: Medical Economics Data, 2006.
14. Package insert. Zelnorm (tegaserod). East Hanover, NJ: Novartis, July 2006.
15. Evans BW, Clark WK, Moore DJ, Whorwell PJ. Tegaserod for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2004;(1):CD003960.
16. Food and Drug Administration. FDA Health Advisory. www.fda.gov/medwatch/ safety/2007/safety07.htm Zelnorm (accessed 2007 Apr 11).
17. Perentesis GP, Crawford DF, Engelke KJ, Osama H, Ueno R. Effects of lubiprostone, a novel GI chloride channel activator, on isolated smooth muscle (abstract). Neurogastroenterol Motil 2005;17:625.
18. Cuppoletti J, Malinowska DH, Tewari KP, et al. SPI-0211 activates T84 cell chloride transport and recombinant human ClC-2 chloride currents. Am J Physiol Cell Physiol 2004;287:C1173-83.
19. Ueno R, Osama H, Habe T, Engelke KJ, Patchen ML. Oral SPI-0211 increases fluid secretion and chloride concentration without altering serum electrolyte levels (abstract). Gastroenterology 2004;126(suppl 2):A298.
20. Camilleri M, Bharucha AE, Ueno R, et al. Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. Am J Physiol Gastrointest Liver Physiol 2006;290:G942-7.
21. Package insert. Amitiza (lubiprostone). Bethesda, MD: Sucampo Pharmaceuticals, March 2006.
22. Crawford DF, Perentesis GP, Engelke KJ, Kawai Y, Ueno R. Pharmacokinetic profile of lubiprostone, a selective GI chloride channel activator, after a single oral dose in multiple animal species (abstract). Neurogastroenterol Motil 2005;17:625.
23. Johanson JF, Gargano MA, Patchen ML, Ueno R. Efficacy and safety of a novel compound, RU-0211, for the treatment of constipation (abstract). Gastroenterology 2002;122(suppl 1):A-315.
24. Johanson JF, Gargano MA, Holland PC, Patchen ML, Ueno R. Phase III efficacy and safety of lubiprostone, a novel chloride channel activator, for the treatment of constipation (abstract). Gastroenterology 2003;124(suppl 1):A-48.
25. Johanson JF, Gargano MA, Holland PC, Patchen ML, Ueno R. Phase III study of lubiprostone, a chloride channel-2 (ClC-2) activator for the treatment of constipation: safety and primary efficacy (abstract). Gastroenterology 2005;100(suppl 2):S-328-9.
26. Johanson JF, Gargano MA, Holland PC, Patchen ML, Ueno R. Multicenter open-label study of oral lubiprostone for the treatment of chronic constipation (abstract). Am J Gastroenterol 2005;100(suppl 7):S-331.
27. Johanson JF, Gargano MA, Holland PC, Patchen ML, Ueno R. Phase III, randomized withdrawal study of RU-0211, a novel chloride channel activator for the treatment of constipation (abstract). Gastroenterology 2004;126(suppl 2):S100.
28. Johanson JF, Gargano MA, Holland PC, Patchen ML, Ueno R. Initial and sustained effects of lubiprostone, a chloride channel-2 (ClC-2) activator for the treatment of constipation: data from a 4-week phase III study (abstract). Am J Gastroenterol 2005;100(suppl 7):S324-5.
29. Johanson JF, Panas R, Holland PC, Ueno R. Long-term efficacy of lubiprostone for the treatment of chronic constipation (abstract). Gastroenterology 2006;130(suppl 2):A-317.
30. Ueno R, Panas R, Wahle A, Zhu T, Holland PC. Long-term efficacy of lubiprostone for the treatment of chronic constipation in elderly subjects (abstract). Gastroenterology 2006;130(suppl 2):A-188.
31. Ueno R, Joswick TR, Wahle A, Zhu T, Holland PC. Efficacy and safety of lubiprostone for the treatment of chronic constipation in elderly vs non-elderly subjects (abstract). Gastroenterology 2006;130(suppl 2):A-189.
32. Johanson JF, Panas R, Holland PC, Ueno R. A dose ranging, double-blind, placebo-controlled study of lubiprostone in subjects with irritable bowel syndrome and constipation (c-IBS) (abstract). Neurogastroenterol Motil 2006;18:730.